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Introduction
Biological medicines contain a biological substance that is
produced by or derived from a living organism. The active
substances of biologicals are usually larger and more com-
plex than those of chemically derived medicines (non-bio-
logical medicine). Biologicals are used for the treatment of
chronic and life-threatening diseases such as cancer, multi-
ple sclerosis and rheumatoid arthritis. Treatment with bio-
logicals is usually expensive and represents ever-increasing
pharmaceutical expenditures for the third-party payer.
In analogy with the introduction of generics for chem-
ically derived medicines, the expiration of patents of the
first biological medicines opened new hopes for affordable
copies and increased competition. The replicate versions of
a biological medicine ‘‘the so-called biosimilars’’ are
available on the European market since 2006, 2007 and
2008, for growth hormone, erythropoiesis-stimulating
agents and granulocyte-colony stimulating factors,
respectively. In June 2013, the Committee for Medicinal
Products for Human Use (CHMP) recommended granting
marketing authorisations for the first two monoclonal
antibody biosimilars (infliximab).
Most of the available literature on biosimilars has
focused on the critical analysis of their specific market
authorization procedure. Before 2010, almost no literature
addressed theoretical or empirical questions on biosimilar
competition and its subsequent impact on uptake and price
erosion. This editorial looks at these issues and provides an
overview on economic aspects of the new biosimilar
competition.
Can biosimilar competition resemble generic
competition?
A brief reminder of the differences between generics and
biosimilars is required before presenting evidence on bio-
similar competition. Whilst generics are considered to be
exact copies of chemically derived medicines, biosimilars
are considered not identical but rather similar to the orig-
inator medicine [1]. According to the European Medicines
Agency (EMA) approved biosimilars and each reference
medicinal product are expected to have the same safety and
efficacy profile and are generally used to treat the same
conditions [1]. The EMA developed a pioneer pathway for
biosimilar market authorisation, which includes specific
guidelines on how to address similarity for different bio-
logical medicines. Requirements of the biosimilar pathway
do not include all elements of a complete dossier for the
approval of a new medicine but are more stringent than the
requirements for the approval of generics. Owing to these
scaled down market authorisation requirements for bio-
similars, it is expected that pharmaceutical companies can
produce biosimilars at a lower cost while ensuring their
quality, safety and efficacy.
Biosimilar competition 1will most probably differ from
generic competition. First, it is widely accepted that pro-
duction costs for biological medicines are higher than for
chemically derived molecules. In principle, this also holds
for differences in the production costs of biosimilars and ofM.-I. Farfan-Portet (&)  S. Gerkens  I. Lepage-Nefkens 
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generics [2–8]. A possible consequence of these higher
costs is that ultimately fewer firms will produce biosimi-
lars. Today, only one biosimilar is commercialized (San-
doz) in the growth hormone product class. For the
erythropoiesis-stimulating agents and granulocyte colony-
stimulating factors product classes, five and six biosimilars
are being commercialized, respectively. However, only two
different manufacturers (Rentschler Biotechnologie and
Norbitec) produce the five epoetin biosimilars. The same is
true for the filgrastim biosimilars for which three manu-
factures share the production of the six commercialized
products [9, 10]. Another determinant of the overall cost of
a medicine is the information service offered by the mar-
keting authorisation holder. The level of service for the
medical community associated with generics and biosimi-
lars is reportedly low as compared with the originator
product. However, in order to familiarize physicians with
the concept of biosimilarity, high investments in informa-
tion services could still be needed for biosimilar medicines.
Second, the International Nonproprietary Name (INN)
2cannot be used, as for generics [12], to reduce market
failure arising from identification of medicines for bio-
similars and the originator biological medicine. INNs for
biological medicines are more problematic than for
chemically derived medicines because of the lack of a
homogenous chemical structure [13]. INN prescribing is
usually not allowed for biological medicines in Europe [14]
and it is a common practice that the logging of a physician
prescription for biological medicines includes the lot
number and the manufacturers name (brand name) to
ensure their traceability and distinguishability (Article 102
of the medicinal products Directive 2001/83/EU, as
amended by Directive 2010/84/EU) [15]. In addition, there
is a debate within the medical and pharmaceutical com-
munity on whether biosimilars need a distinct INN from
their originator and/or from each other. The European
innovative biotechnology and pharmaceutical industry
associations plead in favour of a distinct INN for biosim-
ilars [16] whereas the European Generics Association
(EGA) argues that comparability of two biologicals is
sufficient to assign the same INN [17]. For currently
available biosimilars in Europe, the naming situation is
rather complex and even confusing. For instance, three
biosimilars for the epoetin class share the same INN
‘‘epoetin alfa’’ of the originator Eprex and two have their
unique INN ‘‘epoetin zeta’’. Biosimilars and originator
medicines share the same INN for filgrastim class and for
the growth hormone (the INN ‘‘filgrastim’’ of Neupogen
and the INN ‘‘somatropin’’ of Humanotrope). 3
Different theoretical frameworks have been used in two
articles to analyse biosimilar competition [6, 7]. Grabowski
et al. [7] use a monopolistic competition model to explain
how large investment costs relating to biosimilar produc-
tion lead to fewer competitors and less price erosion than in
markets facing generic competition. In their paper, Gra-
bowski et al. expect that the price difference between a
biosimilar and an originator medicine will attain 10, 25 and
67 % after market entrance of one, three or twelve bio-
similars, respectively. Chauhan et al. [6] adapt Frank and
Salkever’s [18] generic competition model to reflect bio-
similars competition. Chauhan et al. [6, 7] use a duopolistic
market model (biosimilar and originator) where there is a
degree of product differentiation between the biosimilar
and the originator medicine. Competition between the
originator and the biosimilar depends on the price-sensitive
and non-price-sensitive portion of the market. Given that
there is product differentiation, the originator medicine
benefits from a monopolistic position in the non-price-
sensitive ‘‘loyal’’ market segment. On the contrary, com-
petition between the biosimilar and the originator medicine
exists in the price-sensitive ‘‘non-loyal’’ section of the
market. Compared with price erosion created by generic
competition, the two models predict a lower difference
between the price of the biosimilar and of the originator
product. However, Chauhan et al. expect that larger
experience with biosimilars will enhance competition and
may result in further price erosion.
Have biosimilars led to price erosion?
Current evidence on price differences between the bio-
similar and the originator medicine is limited, probably
because biosimilar competition is a recent phenomenon.
Broadly, price difference between the originator medicine
and the biosimilars ranged between 10 and 35 % (see
Table 1). Rovira et al. [2] use the mean price per daily
defined dosage (DDD) across 24 European countries to
calculate the price differences between the biosimilar and
the originator product. Other studies also provide infor-
mation per country [14, 19], for one molecule and for
different countries [20] or a global estimation [5]. Two
studies reported country-specific information from national
authorities [2, 14].
2 The International Nonproprietary Name (INN) is a unique name
that is globally recognised and is public property (also referred to as
‘‘generic name’’). In principle, the INN is selected only for a single,
well-defined substance that can be unequivocally characterized by a
chemical name (or formula) [11].
3 For the purpose of clarity, in the rest of the text we refer to
erythropoiesis-stimulating agents as epoetin, granulocyte colony-
stimulating factors as filgrastim and growth hormone as somatropin.
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How much biosimilar uptake?
Most information on biosimilar uptake is based on the data
provided by IMS Health [2, 4, 21, 22]. Figure 1 provides
the most recent available information on biosimilar uptake
in a sample of European countries [23]. Market shares for
biosimilars are calculated as a percentage of DDD in each
product class. Product classes include biosimilars and
originator products as well as me-too pharmaceuticals
(second-generation products are excluded). Biosimilar
sales (in DDDs) are still a relatively small segment of the
EU pharmaceutical market, but have strong annual growth
Table 1 Price difference between the originator product and the biosimilars








Moran [5]a NA NA Reported by pharmaceutical
companies
NA NA NA 10–35
Hughes [19] 2009 UK British National Formulary
(BNF)
10–25
Rovira et al. [2]b 2009 Average 24 European
countries
IMS data 17 14.1 35.0




2012 Belgium National authorities 30–34 22 20







NA not available, IMS Intercontinental Marketing Services
a Product- or country-specific information was not mentioned
b Rovira et al. also reported country estimates based on IMS data; for detailed country-specific estimates please refer to their work
Fig. 1 Percentage of sales in
DDD of biosimilars of total
market (biosimilars, reference
product and non-reference
product). Source IMS data 2nd
trimester 2011 [23]. *Only retail
sector. DDD defined daily dose.
Second-generation products not
included
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[23]. Market shares of filgrastim biosimilars are highest in
Austria, Norway and Sweden. Uptake for epoetin biosim-
ilars was highest in Germany, Greece and Sweden. The
uptake of somatropin biosimilar is generally lower than for
the other two product classes (filgrastim and epoetin). This
may be related to the fact that somatropin is used for
growth-hormone-related illnesses which require long-term
treatment whereas medicines containing epoetin and fil-
grastim are used for short-term treatment. The highest
uptake for somatropin biosimilars was found in Sweden,
France and Italy. Belgium, Luxembourg and Portugal are
lingering behind, with no uptake or with uptake limited to
only in one product class (somatropin).
What savings can be attributed to the introduction
of biosimilars?
Rovira et al. [2] mentioned that comparability of estimates
on biosimilar-related savings is limited as the data are
based on different modelling strategies and are dependent
on the hypothesis used by different analysts. In addition,
estimates for Europe mostly come from the pharmaceutical
sector itself and include savings relating to groups of
medicines for which biosimilars are not yet available on
the market (e.g. monoclonal antibodies). Consequently,
there is a lack of independent analyses of the current and
future savings from the use of biosimilars. Several authors
reported estimates from the EGA where savings could
attain up to €1.6 billion conditional on a 20 % price
reduction for five patent-expired biologicals [3, 5, 8, 22].
This rough estimate does not provide information based on
the currently available biosimilars but ratter based on
expectation of their apparition. Moreover, savings are
based on total expenditures neglecting price sensitivity and
its impact on purchased volumes.
A recent study used IMS data to provide estimates on
biosimilar-related savings between 2007 and 2020 for eight
European countries (Germany, France, the UK, Italy,
Spain, Sweden, Poland and Romania) [24]. Expected sav-
ings are calculated for epoetins and for filgrastim for which
biosimilars are already commercialized. Scenarios for
possible savings relating to the future apparition of bio-
similars in the class of monoclonal antibodies were also
included. Expected savings for the eight countries and
between 2007 and 2020 vary from €11.8 billions (slow
penetration and minimal price reduction) to €33.4 billion
(fast penetration and maximal price reduction) [24]. While
these findings provide the most recent estimates on bio-
similar-related savings, they rely on heavy assumptions
concerning outcomes of the German generic pharmaceuti-
cal market (extrapolated to other countries) and to large
savings obtained within the monoclonal antibodies class
(mAbs) for which biosimilars are not yet available on the
market. For many countries, the hypothesis used by the
authors can overestimate biosimilar-related savings as (1)
the Germany generic market is more developed than that of
other countries (and therefore overestimating uptake) and
(2) for complex molecules (such as mAbs) it is not know
whether biosimilars will enter the market immediately after
that the originator patent expires [25].
Discussion points for the future of biosimilar
competition
As for generics the biggest advantage of biosimilars is that
they may offer a less-expensive alternative to an existing
medicine and therefore reduce pharmaceutical expenditure
for the third-party payer. However, regulatory issues, bio-
similar acceptability among physicians, price and reim-
bursement policies as well as supply and demand-side
incentives will ultimately determine the actual level of
biosimilar-related savings.
Theoretical models predicted that biosimilar competi-
tion will lead to less price erosion than that obtained
through generic competition [6, 7]. In line with this theo-
retical prediction, although price erosion arising from
generic competition of up to 80 % has been reported in
countries like the UK and Germany, reported price erosion
from biosimilar competition has not exceeded 35 % [2, 5,
14, 19, 20].
The hypothesis of segmentation for biosimilar markets
is also supported by real-life evidence and may depend on
physician loyalty (and lack of tools to circumvent it),
perception of product differentiation and patient type (new
patients and patients already following a treatment).
Without pharmacist substitution or the possibility to pre-
scribe by INN and if physicians are sceptical to switch a
patient from an originator medicine to a biosimilar, market
uptake for biosimilars can only take place among new
users. Even with regard to treatment-naı¨ve patients, phy-
sicians facing different information or incentives may
overlook the financial advantages of prescribing biosimi-
lars. For instance, because biological medicines are usually
prescribed for life-threatening or chronic illness, patient
cost-sharing is usually limited [14]. Therefore, prescription
decisions based on prices or cost will depend only on
physician attitudes regarding insurer cost (or third-party
payer). Physicians may also be more reluctant to use bio-
similars for certain molecules or populations. For instance,
despite strong competition between originator products in
the growth hormone class (somatropin), it is a common
practice to maintain patients on the same treatment.
Somatropin is mostly prescribed to children and a learning
process related to the companion medicine device is an
226 M.-I. Farfan-Portet et al.
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important part of the compliance process [14]. Some
authors reported that one barrier limiting the uptake of the
somatropin biosimilar resided on the difference between
the device of the biosimilar and of the originator medicine
[4, 14].
Gaining shares in the price-sensitive part of the market
as well as reducing (at least to some extent) market seg-
mentation will critically depend on experience with bio-
similars that will in return influence perception of product
differentiation. This may require transmitting to healthcare
professionals clinical data proving the effectiveness and
safety of biosimilars, including data obtained after
switching. Moreover, appropriate investment in commer-
cial and marketing strategies will be needed to make pre-
scribers aware of the possibilities and qualities of these less
expensive alternatives. Compared with generics, a different
marketing approach may be needed as biosimilars are
considered as molecules that are more complex and
because policy measures to circumvent physician loyalty
are currently limited. These elements seem to highlight that
biosimilar competition may resemble more that of me-too
pharmaceuticals than that of generic medicines [4, 6, 7].
Expiry of market exclusivity of major biological
blockbusters is the main driver surrounding the interest in
the development of the biosimilar industry. Many leading
‘‘traditional’’ originator companies are already developing
biosimilars. Companies’ experience in the production of
complex biologicals may lead to optimized production of
biosimilars at low cost and even drive originators to
reconsider their production method. Originator companies
will probably produce biosimilars in new product classes
(for instance mAb) and may have different marketing
strategies towards health professionals than current bio-
similar manufacturers. Whether these companies will use
the same strategies and provide similar levels of informa-
tion services for their innovator products and for biosimi-
lars remains an open question. Yet, this may change the
current perception of biosimilars and even the current
biosimilar business model.
The challenge for policy makers in the coming years
will be to set effective measures leading to improved bio-
similar uptake. Policy makers need to envisage that policy
measures that have been successful in increasing generic
use, such as INN prescribing, may not be currently
appropriate to promote biosimilar uptake. Expectations on
future savings related to forthcoming biosimilars are a key
driver for interest and concern from national authorities on
biosimilar current market penetration. Lack of market
penetration of the currently available biosimilars may be
seen as a lost opportunity, less in terms of current savings
than as a barrier for potential future savings. In line with
this, more evidence needs to be provided on the impact of
public policies in stimulating biosimilar uptake.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Appendix
A structured review of the literature was performed up to 8
November 2012 in MedLine OVID and PUBMED with the
following terms: ‘‘biosimilar*’’ or ‘‘biosimilar pharma-
ceuticals/MeSH’’. A complementary search was done in
institutional and grey literature databases (DRIVER, OA-
ISTER and Google Scholar). Only articles containing
empirical data, theoretical models as well as discussions or
reviews were included. From 735 initially identified ref-
erences, 35 articles and one book remained. Full texts were
then searched and inclusion/exclusion criteria were applied
on full texts. Abstract were only available for nine articles
[26–34]; three articles [35–37] could not be accessed.
Seven articles did not comply with the inclusion criteria
[38–44]. In addition five articles discussing cost-effec-
tiveness of biosimilars [45–49] were not included because
evidence on efficacy and safety was not analysed as a part
of this review. A total of 11 articles and one book were
considered relevant and were included in our review. We
also included information from the project group Market
Access and Uptake of Biosimilars [23] and from one recent
report on biosimilar uptake in Belgium [14].
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